Lead Product(s) : Hyaluronic Acid,Lidocaine
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Princess Volume Plus (hyaluronic acid) dermal filler and Lidocaine with the intention to confirm the efficacy and safety in respect of mid-facial volume insufficiency and/or mid-facial profile deficient participants.
Product Name : Princess Volume Plus
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 12, 2023
Lead Product(s) : Hyaluronic Acid,Lidocaine
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Saypha Volume Lidocaine
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Saypha® VOLUME Lidocaine for Midface Augmentation
Details : Saypha Volume Lidocaine is a Peptide-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Midface volume deficiency.
Product Name : Undisclosed
Product Type : Peptide-drug Conjugate
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : Saypha Volume Lidocaine
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Croma’s botulinum toxin submission in Europe is based on 2 completed randomized, placebo-controlled Phase III pivotal trials (BLESS I and II) that enrolled a total of 917 subjects in Europe and the US.
Product Name : BoNT/A-DP
Product Type : Protein
Upfront Cash : Inapplicable
July 08, 2020
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)
Details : Botulinum Toxin Type A is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glabellar Frown Lines.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 14, 2019
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
Details : Botulinum Toxin Type A is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glabellar Frown Lines.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 09, 2016
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II
Details : Botulinum Toxin Type A is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glabellar Frown Lines.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 09, 2016
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable